Skip to main content

Propel FDA Approval History

FDA Approved: Yes (First approved August 15, 2011)
Brand name: Propel
Generic name: mometasone furoate
Dosage form: Implant
Company: Intersect ENT, Inc.
Treatment for: Sinusitis

Propel (mometasone furoate) is a corticosteroid implant offering localized, controlled drug delivery for chronic sinusitis patients.

Development timeline for Propel

Aug 15, 2011Approval Intersect ENT Announces U.S. Food and Drug Administration Approval for Propel - First Drug Releasing Implant for Chronic Sinusitis Patients

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.